Subscribe to RSS
DOI: 10.1055/s-0030-1265295
Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective
Publication History
Publication Date:
26 October 2010 (online)
![](https://www.thieme-connect.de/media/sth/201007/lookinside/thumbnails/10.1055-s-0030-1265295-1.jpg)
ABSTRACT
Thrombin generation is a key process that determines the extent of a hemostatic plug or a thrombotic process. The ensuing thrombin burst is crucial for the formation of a stable fibrin clot. During its active life, thrombin exerts a multitude of highly regulated actions on the blood and the vessel wall, among which is the clotting of fibrinogen. The inappropriate generation of thrombin may lead to pathological processes, foremost of which are hemorrhagic or thrombotic diseases. The coagulation system is usually investigated by means of two in vitro classical clotting tests, the activated partial thromboplastin time and prothrombin time. These assays assess only the time taken to form a clot and do not entirely reflect global hemostatic balance. They permit identification of connectivity between the component activities identified as required for plasma coagulation and define the concept of intrinsic and extrinsic coagulation pathways, which converge at the step of formation of the prothrombinase complex. However, the mechanisms established by in vitro tests are not always mirrored in the human pathologies associated with bleeding or thrombosis. The recent development of newer tests based on the continuous registration of thrombin generation (TG) under in vitro conditions that mimic more closely what occurs in vivo prompted us to reinvestigate the balance between procoagulants and anticoagulants in patients. Thrombin generation assays (TGA) not only provide an overall assessment of hemostasis, but they also target potential extrahemostatic effects of the generated thrombin, a potent agonist of a multitude of cellular activation pathways. Moreover, estimation of an individual's thrombin generation potential may correlate more closely with a hyper- or hypocoagulable phenotype, compared with traditional coagulation tests. In this review, we discuss to what extent TG can be expected to reflect the clotting function of blood, the development and use of different TGA systems suitable for detecting changes in the kinetics of thrombin generation, and the test's clinical utility for patients with hemophilia or von Willebrand disease.
KEYWORDS
Thrombin generation assay - coagulation - hemophilia - von Willebrand disease
REFERENCES
- 1 MacFarlane R G, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953; 6(1) 3-8
- 2 Pitney W R, Dacie J V. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. J Clin Pathol. 1953; 6(1) 9-14
- 3 Hemker H C, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995; 74(1) 134-138
- 4 Hemker H C, Giesen P, AlDieri R et al.. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002; 32(5-6) 249-253
- 5 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia. 2008; 14(Suppl 3) 83-92
- 6 Salvagno G L, Astermark J, Lippi G et al.. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?. Haemophilia. 2009; 15(1) 290-296
- 7 Beltrán-Miranda C P, Khan A, Jaloma-Cruz A R, Laffan M A. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia. 2005; 11(4) 326-334
- 8 Jayandharan G R, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008; 34(1) 128-141
- 9 Váradi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003; 1(11) 2374-2380
- 10 Turecek P L, Váradi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003; 33(1) 16-22
- 11 Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008; 14(Suppl 4) 20-27
- 12 Terraube V, O'Donnell J S, Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010; 16(1) 3-13
- 13 Hollestelle M J, Thinnes T, Crain K et al.. Tissue distribution of factor VIII gene expression in vivo—a closer look. Thromb Haemost. 2001; 86(3) 855-861
- 14 Collins P W, Blanchette V S, Fischer K et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost. 2009; 7(3) 413-420
- 15 Biggs R A, Douglas A S, MacFarlane R G, Dacie J V, Pitney W R, Merskey . Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952; 2(4799) 1378-1382
- 16 van den Berg H M, De Groot P H, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007; 5(Suppl 1) 151-156
- 17 Vicente V. Factor VIII half-life and intensity of treatment in hemophilic patients. Haematologica. 2005; 90(4) 437
- 18 Franchini M, Montagnana M, Targher G et al.. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost. 2009; 35(3) 307-312
- 19 Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia. 2009; 15(Suppl 1) 2-7
- 20 Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia. 2010; 16(2) 223-230
- 21 Schwaab R, Oldenburg J, Kemball-Cook G et al.. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol. 2000; 109(3) 523-528
- 22 van Dijk K, van der Bom J G, Lenting P J et al.. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005; 90(4) 494-498
- 23 Molho P, Rolland N, Lebrun T The French Study Group et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group.secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia. 2000; 6(1) 23-32
- 24 Plug I, van der Bom J G, Peters M et al.. Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood. 2004; 104(12) 3494-3500
- 25 Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell J S, Jenkins P V. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia. 2010; 16(4) 671-674
- 26 Berntorp E, Salvagno G L. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost. 2008; 34(7) 670-682
- 27 Bolton-Maggs P H, Pasi K J. Haemophilias A and B. Lancet. 2003; 361(9371) 1801-1809
- 28 Aledort L M, Haschmeyer R H, Pettersson H. The Orthopaedic Outcome Study Group . A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med. 1994; 236(4) 391-399
- 29 Ljung R, Petrini P, Nilsson I M. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand. 1990; 79(2) 196-200
- 30 Nilsson I M, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232(1) 25-32
- 31 Nichols W C, Amano K, Cacheris P M et al.. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood. 1996; 88(4) 1183-1187
- 32 Brummel-Ziedins K, Vossen C Y, Rosendaal F R, Umezaki K, Mann K G. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost. 2005; 3(7) 1472-1481
- 33 Nadeau J H. Modifier genes and protective alleles in humans and mice. Curr Opin Genet Dev. 2003; 13(3) 290-295
- 34 Ginsburg D. Identifying novel genetic determinants of haemostatic balance. J Thromb Haemost. 2005; 3(8) 1561-1568
- 35 Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost. 2008; 6(3) 486-493
- 36 Santagostino E, Mancuso M E, Tripodi A et al.. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost. 2010; 8(4) 737-743
- 37 Colvin B T, Astermark J, Fischer K Inter Disciplinary Working Group et al. European principles of haemophilia care. Haemophilia. 2008; 14(2) 361-374
- 38 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia. 2008; 14(Suppl 3) 83-92
- 39 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?. Br J Haematol. 2008; 142(6) 889-903
- 40 Dargaud Y, Béguin S, Lienhart A et al.. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005; 93(3) 475-480
- 41 Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia. 2003; 9(4) 353-359
-
42 Berntorp E.
Factor VIII concentrates . In: Forbes CD, Aledort L Haemophilia. London, United Kingdom; Chapman & Hall 1997: 181-192 - 43 Barrowcliffe T W. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost. 1993; 70(5) 876-877
- 44 White GC 11, Shapiro A D, Kurczynski E M, Kim H C, Bergman G E. The Mononine Study Group . Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with haemophilia B. Thromb Haemost. 1995; 73(5) 779-784
- 45 Dunn A L, Abshire T C. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol. 2006; 115(3–4) 162-171
- 46 Bolton-Maggs P H. Optimal haemophilia care versus the reality. Br J Haematol. 2006; 132(6) 671-682
- 47 Bassus S, Wegert W, Krause M et al.. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Platelets. 2006; 17(6) 378-384
- 48 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4) 418-435
- 49 Hall M. Haemophilia complicated by an acquired circulating anticoagulant: a report of three cases. Br J Haematol. 1961; 7 340-348
- 50 Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia. 2007; 13(Suppl 5) 69-72
- 51 White II G C, Rosendaal F, Aledort L M, Lusher J M, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee . Definitions in hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001; 85(3) 560
- 52 Berntorp E, Shapiro A, Astermark J et al.. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006; 12(Suppl 6) 1-7
- 53 Astermark J, Oldenburg J, Escobar M, White II G C, Berntorp E. Malmö International Brother StudyGroup . The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005; 90(7) 924-931
- 54 Mannhalter C. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005; 90(7) 869A
- 55 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004; 10(Suppl 2) 10-16
- 56 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009; 15(1) 3-10
- 57 Turecek P L, Váradi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation assay. Pathophysiol Haemost Thromb. 2003; 33(1) 16-22
- 58 Váradi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003; 1(11) 2374-2380
- 59 Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia. 2008; 14(4) 782-786
- 60 Dargaud Y, Lienhart A, Meunier S et al.. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia. 2005; 11(5) 552-558
- 61 Klintman J, Berntorp E, Astermark J. ON BEHALF OF THE MIBS STUDY GROUP* . Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia. 2009; , October 30 (Epub ahead of print)
- 62 Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009; 90(5) 576-582
- 63 Aljamali M N, Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Haemophilia. 2009; 15(6) 1318-1326
- 64 Brummel-Ziedins K E, Whelihan M F, Gissel M, Mann K G, Rivard G E. Thrombin generation and bleeding in haemophilia A. Haemophilia. 2009; 15(5) 1118-1125
- 65 Eichinger S, Lubsczyk B, Kollars M et al.. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest. 2009; 39(8) 707-713
- 66 Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia. 2009; 15(4) 904-910
- 67 Rosenthal R L, Dreskin O H, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood. 1955; 10(2) 120-131
- 68 Bolton-Maggs P H, Young Wan-Yin B, McCraw A H, Slack J, Kernoff P B. Inheritance and bleeding in factor XI deficiency. Br J Haematol. 1988; 69(4) 521-528
- 69 Bolton-Maggs P H. Factor XI deficiency—resolving the enigma?. Hematology Am Soc Hematol Educ Program. 2009; 97-105
- 70 Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009; 7(Suppl 1) 84-87
-
71 Furie B, Furie B C.
Molecular basis of blood coagulation . In: Hoffman H, Benze EJ, Shattil SJ, et al Hematology, Basic Principles and Practice. 5th ed. Philadelphia, PA; Churchill Livingstone-Elsevier 2009: 1819-1836 - 72 Emsley J, McEwan P A, Gailani D. Structure and function of factor XI. Blood. 2010; 115(13) 2569-2577
- 73 Ghosh K, Mota L, Shetty S, Kulkarni B. Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation. Blood Coagul Fibrinolysis. 2008; 19(6) 577-580
- 74 Mitka M. Guidelines for von Willebrand disease urge routine screening for bleeding. JAMA. 2008; 299(16) 1890
- 75 Terraube V, O'Donnell J S, Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010; 16(1) 3-13
- 76 Mannucci P M. Treatment of von Willebrand's disease. N Engl J Med. 2004; 351(7) 683-694
- 77 Béguin S, Kumar R, Keularts I, Seligsohn U, Coller B S, Hemker H C. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood. 1999; 93(2) 564-570
- 78 Rugeri L, Beguin S, Hemker C et al.. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica. 2007; 92(12) 1639-1646
- 79 Lippi G, Franchini M, Salvagno G L, Montagnana M, Poli G, Guidi G C. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. J Thromb Thrombolysis. 2008; 26(2) 150-153
- 80 Quiroga T, Goycoolea M, Giesen P L et al.. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages. Pathophysiol Haemost Thromb. 2003; 33(1) 30-35
- 81 Keularts I M, Hamulyak K, Hemker H C, Béguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost. 2000; 84(4) 638-642
- 82 Al Dieri R, Peyvandi F, Santagostino E et al.. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002; 88(4) 576-582
- 83 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?. Br J Haematol. 2008; 142(6) 889-903
- 84 Spaanderman M E, Van Beek E, Ekhart T H et al.. Changes in hemodynamic parameters and volume homeostasis with the menstrual cycle among women with a history of preeclampsia. Am J Obstet Gynecol. 2000; 182(5) 1127-1134
- 85 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia. 2008; 14(Suppl 3) 83-92
- 86 Dargaud Y, Luddington R, Gray E et al.. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol. 2007; 139(2) 303-309
Gian Luca SalvagnoM.D.
Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degl-i Studi di Verona
Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 – Verona, Italy
Email: gsalvagno77@yahoo.it
Email: gianluca.salvagno@univr.it